Learn how and why Atom Bioscience is developing a new treatment for gout — and the impact it may have on millions of lives.

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.) is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule drugs for treatment of inflammatory and metabolic diseases, such as chronic gout and non-alcoholic steatohepatitis (NASH) for which there are no effective treatments.

Atom’s lead therapy, ABP-671, for chronic gout, is more potent and significantly less toxic than existing drugs, and is poised to enter global Phase 3 trials in 2023. Another compound, ABP-6016, has demonstrated safety and efficacy in preclinical trials for NASH, which is projected to become the most common cause of liver disease.

Latest News from Atom Bioscience

24 May, 2023
Fierce Biotech: Atom Bioscience Hopes to Make Big Bang with New Gout Awareness Campaign
22 May, 2023
Atom Bioscience Marks Gout Awareness Day by Urging Increased Patient Education on Debilitating Effects of the Chronic Disease
03 April, 2023
Atom Bioscience Names UC San Diego Professor Robert Terkeltaub, M.D., to its Scientific Advisory Board
01 March, 2023
Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor for Chronic Gout
More Atom News